Evaluating Quality Adjusted Life in Acute Ischemic Stroke Patients: Insights from Door-to-Needle Time Observations

Aim/Background: To assess the safety and effectiveness of tenecteplase in acute ischemic stroke patients treated within 3.5 hr of symptom on set, evaluating its potential as a cost-effective treatment option. Materials and Methods: Study population: 38 patients over 35 years old, Demographics: Predominantly male (62.5%), age range 56-65 years, Lifestyle analysis: 58.3% smokers, 44.7% alcohol consumers, Treatment: Tenecteplase administered within 3.5 hr of symptom onset. Results: Patient Outcomes: 94.73% achieved independence in daily activities; 56.25% experienced shorter hospital stays (3-5 days); 81.05% positive outcomes at discharge; 94.21% improvement after one month; Quality-Adjusted Life Year (QALY) analysis showed significant improvement; Demonstrated cost-effectiveness compared to other thrombolytic treatments. Conclusion: Tenecteplase emerges as a safe and cost-effective treatment for Acute Ischemic Stroke, demonstrating significant improvements in neurological recovery, patient independence, and potential reduction in healthcare costs while enhancing patient quality of life.